LitAlert ~~ GeneLit.com

    • Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience.
    • Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, Heitz F.
    • Gynecol Oncol Rep. 2022 Feb 2 [eCollection 2022 Apr];40:100939. doi: 10.1016/j.gore.2022.100939.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J.
    • Cochrane Database Syst Rev. 2022 Feb 16;2:CD007929. doi: 10.1002/14651858.CD007929.pub4.
    • Review
    • Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
    • Bellcross CA.
    • Obstet Gynecol Clin North Am. 2022 Mar;49(1):117-147. doi: 10.1016/j.ogc.2021.11.005.
    • Review
    • Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer.
    • Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Thomssen C, Müller V, Fehm TN, Belleville E, Bader S, Untch M, Welslau M, Thill M, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R, Hartkopf AD.
    • Geburtshilfe Frauenheilkd. 2022 Feb 11 [eCollection 2022 Feb];82(2):215-225. doi: 10.1055/a-1724-9569.